Creating a Public-Private Partnership to Support Development of Anti-Cancer Therapies for Ultra-Rare Tumor Indications
FNIH, NCI, and FDA Public Meeting Notice
On August 24, 2023, the Foundation for the National Institutes of Health (FNIH), the National Cancer Institute (NCI), and the Oncology Center of Excellence at the Food and Drug Administration (FDA) conducted a virtual meeting to discuss plans for creating a public-private partnership (PPP) to guide and support the development of new treatments for patients with ultra-rare cancers. Many pediatric and adult ultra-rare cancers have actionable oncogenic drivers not present in more common cancers; however, there is limited economic incentive to encourage concerted and coordinated efforts to develop drugs for these ultra-rare cancers.
During this multi-stakeholder meeting, participants discussed options for a collaborative open-science, open-drug development process for targeted therapies for ultra-rare cancer indications. FNIH will solicit feedback and suggestions from the ultra-rare cancer community on the proposed PPP plans and gauge interest and resources available for drug development in this arena.
Meeting Date: August 24, 2023
Meeting Time: 11:00-15:00 US Eastern Time
Meeting Format: Virtual
Workshop Materials
If you have any questions prior to the meeting, please feel free to contact the FNIH team: Stacey Adam (sadam@fnih.org), Dana Connors (dconnors@fnih.org), and Katherine Lambertson (klambertson@foundationfornih.org).
Further Information
- FDA Oncology Center of Excellence: Project Catalyst